Elizabeth Tan-Chiu, MD
Hematology & Oncology · Tampa, FLNPI 1538113931
Payments from drug & device makers
What this record shows
27 manufacturers reported payments, led by Eli Lilly at 50.2% of the total. 2025 is the largest year on record at $1,434, 4.6 times the $309 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in FL, where the typical reported total is $3,884.
Across 45 payments — averaging $55.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1K
- AstraZeneca$239
- Takeda Pharmaceuticals U.S.A., Inc.$136
- Lilly USA, LLC$121
- Novocure Inc.$78
- Pfizer$63
- plus $603 from 21 others
Across 6 payments — averaging $1613.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$7K
- Puma Biotechnology, Inc.$3K
What the payments were for
- Consulting fees$1,25050%
- Food & beverage$1,24150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 1 | $1,250 |
| AstraZeneca | 7 | $239 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $136 |
| Lilly USA, LLC | 1 | $121 |
| Novocure Inc. | 1 | $78 |
| Pfizer | 1 | $63 |
| Myriad Genetic Laboratories, Inc. | 1 | $57 |
| Novartis | 3 | $54 |
| Sanofi | 3 | $54 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $47 |
| Bristol Myers Squibb | 2 | $42 |
| Boehringer Ingelheim | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Bayer | 2 | $34 |
| EMD Serono, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Rigel Pharmaceuticals, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Merck | 1 | $18 |
| EUSA Pharma (US) LLC | 1 | $16 |
| Tolmar Pharmaceuticals, Inc. | 1 | $15 |
| Agios Pharmaceuticals, Inc. | 1 | $15 |
| Partner Therapeutics, Inc. | 1 | $14 |
| Amgen | 1 | $14 |
| Secura Bio, Inc. | 2 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,491 in reported general payments places this provider in the 40th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 16 | $348 |
| Anastrozole | 12 | $289 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Tampa
- Damian LaberTampa$753K
- Richard KimTampa$637K
- Ariel Grajales CruzTampa$625K
- Julio ChavezTampa$383K
- David SallmanTampa$285K
- Daniel Kerr IiTampa$193K
- Bijal ShahTampa$150K
- Nikesh ShahTampa$141K
- Kendra SweetTampa$139K
- Hayder SaeedTampa$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.